of Eli Liy. Take a map. Take a look.Up over 3%. The U pharmaceutical giant releasing more data on its obesity pill. Patients with obesity and diabetes lost about 10 and a half% of their body weight.The new data clears the way for Lily to seek regulatory approval. Guggenheim analyst Sheamus Fernandez joins us now. He's got a buy rating on Lily.Price target of 875. So, how do you take this news. You know, we got the previous data.there seemed to be some disappointment perhaps at the average weight loss. Has t ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Shares of pharmaceutical giant Eli Lilly and Co (NYSE:LLY) are on the rise today, up 3.7% at $720.07 at last check. The company's daily weight-loss pill, orforglipron, met its main goal in a late-stage trial, helping type 2 diabetes patients shed 10.5% of their body weight in 72 weeks. This was the last study needed for Eli Lilly to seek approval for the drug globally. On the charts, LLY has been climbing since its August 8th 52-week low of $623.78, heading for its 10th gain in the last 12 sessions. The sha ...

周二，礼来(LLY.US)股价一度涨4%，截至发稿，该股涨超3%，报718.74美元。消息面上，该公司宣 布，其每日口服减肥药Orforglipron在一项针对肥胖和2型糖尿病患者的后期临床试验中成功达到主要研 究目标，计划明年在全球推出该药物。在为期72周的研究中，接受Orforglipron最高剂量的患者平均减 重10.5%，而安慰剂组减重2.2%。 ...

智通财经APP获悉，周二，礼来(LLY.US)股价一度涨4%，截至发稿，该股涨超3%，报718.74美元。消 息面上，该公司宣布，其每日口服减肥药Orforglipron在一项针对肥胖和2型糖尿病患者的后期临床试验 中成功达到主要研究目标，计划明年在全球推出该药物。在为期72周的研究中，接受Orforglipron最高 剂量的患者平均减重10.5%，而安慰剂组减重2.2%。 ...

Let's get to Jim and stop trading. One of my favorite executives is David Ricks from Eli Liy. He came on after that last trial and that was the uh a trial for weight loss obviously August 7225.He said look our stocks shouldn't be down that much. I mean there's a lot more things in the pipeline. He then bought 1,632 shares at 645 uh August 12th.He said saying basically look we're we're not bad. Well, of course, the new tri another trial came out today, August 26. Same kind, the misinformation thing is so leg ...

Group 1 - US stock indices opened slightly lower, with Dow down 0.13%, S&P 500 down 0.06%, and Nasdaq down 0.04% [1] - Eli Lilly's oral GLP-1 drug orforglipron achieved positive results in Phase 3 clinical trials, leading to plans for a global regulatory submission within the year [4] - South Korea's Korean Air signed a $50 billion procurement agreement with Boeing for 103 new-generation aircraft and engine maintenance services over the next 20 years [5] Group 2 - Beike reported a 11.3% year-on-year increase in revenue for Q2, totaling 26 billion yuan, while NON-GAAP net profit decreased by 32.4% to 1.82 billion yuan [6]

The most-read strategy and economics research this week... Greed & fear The slightly better than anticipated July inflation data means that Fed easing expectations have picked up marginally. Still for a data-dependent Fed not willing to project forward, which is more or less where the Powell-led Fed has been of late, there is still an argument to stay on hold since the reality is that reported inflation is still well above the 2% YoY target. India Strategy The GST rate rationalization is expected 4QCY25. As ...

如何推动更加便捷、更加有效的体重管理解决方案落地，成为建设健康中国进程中必须正视和破解的关 键问题。 本报讯(记者梁傲男)当前，全球糖尿病患病率持续攀升，成为威胁人类健康的重要公共卫生问题。据相 关数据，我国成人糖尿病患病率已达到11.9%，其中大多数为2型糖尿病患者。在这些患者中，超过六 成同时合并超重或肥胖。 对于合并2型糖尿病的超重或肥胖患者而言，肥胖带来的多种并发症风险，会给糖尿病患者的长期健康 结局带来更大不确定性。据相关研究，体重下降超过10%，2型糖尿病的缓解率明显增加。不过，在现 实中，这类患者的减重难度往往更大，依靠饮食控制、运动干预等传统方式往往难以取得持久成效。 在2024年版《糖尿病患者体重管理专家共识》中，专家指出，生活干预对体重的影响有限，同时受到超 重或肥胖以及糖尿病困扰的患者应该重视具有体重获益降糖药物的使用。美国糖尿病协会诊疗标准建 议，这类患者选择降糖药物时，优先考虑对体重有益的药物，并推荐优先选择具有较强减重作用的 GLP1类药物。从临床应用来看，目前主流GLP-1类药物仍以注射剂型为主，而有限的口服药物则需要 在空腹状态下使用，且服药后须禁食饮水半小时，在很大程度上影响 ...

在安全性方面，公司指出orforglipron的耐受性特征与GLP-1受体激动剂类其他药物一致。但三个剂量水 平因不良事件导致的治疗中止率为6.1%-10.6%，而安慰剂组为4.6%。与此同时，6mg、12mg和36mg剂 量组的总体治疗中止率分别为19.1%、22.3%和20.5%，安慰剂组为20%。"随着ATTAIN-2试验的完成， 礼来现已具备启动orforglipron全球注册申报所需的完整临床数据包，"公司声明称，并补充说完整研究 结果将在未来的医学会议上公布并提交发表。 本月初，礼来曾宣布该实验性疗法在其ATTAIN-1三期试验中达到主要终点和所有关键次要终点，最高 剂量组72周内实现平均减重12.4%(27.3磅)。但由于该读数未达到华尔街的高预期，礼来股价应声下跌。 礼来(LLY.US)周二宣布，其口服减肥疗法orforglipron在第三阶段3期试验中达到了主要目标，该公司将 就此推进这款每日一次GLP-1受体激动剂的全球注册申报。 礼来援引其ATTAIN-2三期试验的顶层数据称，根据方案集分析，orforglipron在最高剂量下实现了主要 终点，72周内平均减重达22.9磅(10.5%) ...